All News
Filter News
Found 659 articles
-
Even at its highest dose, Vir Biotechnology’s investigational flu shot failed to significantly outperform placebo at preventing influenza A illness in a mid-stage study.
-
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
7/20/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.
-
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
7/19/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that results from its Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).
-
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
7/17/2023
Alnylam Pharmaceuticals, Inc. announced updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy.
-
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
7/12/2023
Ultragenyx Pharmaceutical Inc. today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023.
-
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
7/6/2023
Brii Biosciences Limited announced that it has entered into license agreements with VBI Vaccines, Inc., expanding the companies' collaboration in the hepatitis B virus field.
-
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
7/6/2023
Brii Biosciences Limited provided updates on its diverse pipeline of infectious disease and central nervous system disease candidates and announced a pivotal leadership transition that will further advance its strategic priorities.
-
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
7/5/2023
VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced the expansion of its hepatitis B partnership with Brii Biosciences .
-
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
6/30/2023
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis.
-
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
6/29/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023.
-
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
6/25/2023
Brii Biosciences Limited announced that its strategic partners, Vir Biotechnology, Inc. and VBI Vaccines, Inc., presented results from multiple clinical studies for the treatment and prevention of chronic hepatitis B viral infection at the European Association for the Study of the Liver Congress 2023 that further support the clinical evaluation of Brii Bio's assets as a potential best-in-class functional cure for chronic HBV infection.
-
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
6/24/2023
Vir Biotechnology, Inc. announced new data from its robust hepatitis B and D virus portfolio that were presented at the EASL™ Congress.
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
6/7/2023
Vir Biotechnology, Inc. announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus and hepatitis D virus have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2023, taking place in Vienna from June 21-24.
-
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
6/5/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.
-
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
5/20/2023
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced new results from an interim analysis of exploratory data from the open-label extension period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy.
-
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
5/17/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT.
-
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
5/15/2023
Vir Biotechnology, Inc. announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer.
-
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
5/11/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults.
-
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
5/9/2023
Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, reported first quarter 2023 financial and operating results.
-
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
5/9/2023
Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, announced the appointment of George Scangos, Ph.D., to its Board of Directors.